Destiny Pharma on track for commercial agreement for NTCD-M3 drug
Destiny Pharma PLC on Thursday said partnering negotiations for its NTCD-M3 clinical programme are nearing finalisation.
The Brighton, England-based clinical-stage biotechnology company, focused on the...
Thu, 22/12/2022 - 11:25